LCH in Children

What is Langerhans Cell Histiocytosis (LCH)?

What is Langerhans Cell Histiocytosis (LCH)?

What is Langerhans Cell Histiocytosis (LCH)
Langerhans Cell Histiocytosis (LCH) is the most common of the histiocytic disorders and occurs when the body accumulates too many immature Langerhans cells, a subset of the larger family of cells known as histiocytes. Langerhans cells are a type of white blood cell that normally help the body fight infection. In LCH, too many Langerhans cells are produced and build up in certain parts of the body where they can form tumours or damage organs. Most data support the concept that LCH is a diverse disease characterized by a clonal growth of immature Langerhans cells, that in more than half the cases have a mutation called V600E of the BRAF gene and related mutations in some other cases. V600E is found in tumours such as melanoma and thyroid cancer.
There has been some controversy about whether LCH is a cancer, but it is classified as such, and sometimes requires treatment with chemotherapy is not a fully developed malignant cancer. It is not contagious, nor is it believed to be inherited.

About 50 children in the UK develop LCH each year. It can affect children of any age, and is more common in boys than in girls.

LCH is an unusual condition. It has some characteristics of cancer but, unlike almost every other cancer, it may spontaneously resolve in some patients while being life-threatening in others. LCH is classified as a cancer and sometimes requires treatment with chemotherapy. LCH patients are therefore usually treated by children’s cancer specialists (paediatric oncologists/ haematologists).
The vast majority of children will recover completely from LCH.

 

Histiocytosis was first described in the medical literature in the mid to late 1800s. Through the years, it has been known by various names, such as histiocytosis-X, eosinophilic granuloma, Abt-Letterer-Siwe disease, Hashimoto-Pritzger disease, and Hand-Schüller-Christian syndrome. In 1973, the name Langerhans Cell Histiocytosis (LCH) was introduced. This name was agreed upon to recognize the central role of the Langerhans cell.

LCH is believed to occur in 1:200,000 children, but any age group can be affected, from infancy through adulthood. In new born and very young infants, it occurs in 1-2 per million. It is, however, believed to be under-diagnosed, since some patients may have no symptoms, while others have symptoms that are mistaken for injury or other conditions. It occurs most often between the ages of 1-3 years and may appear as a single lesion or can affect many body systems, such as skin, bone, lymph glands, liver, lung, spleen, brain, pituitary gland and bone marrow.

Information has been collected in various studies which show that bone involvement occurs in approximately 78% of patients with LCH and often includes the skull (49%), hip/pelvic bone (23%), upper leg bone (17%) and ribs (8%). Skin LCH is seen in as many as 50% of patients. Lung lesions are seen in 20% to 40% of patients, while 30% of patients have lymph node involvement.

LCH is divided into two main groups

LCH is divided into two main groups

Symptoms depend on the location and severity of involvement. It is usually diagnosed with a tissue biopsy, in addition to other testing, such as x-rays and blood studies. A biopsy of an involved site is necessary to make a definitive diagnosis.

While some limited cases of histiocytosis may not require treatment, for patients with more extensive disease, chemotherapy may be necessary. Haematologists and oncologists, who treat cancer, also treat children with Langerhans cell histiocytosis.

Most patients with LCH will survive this disease. LCH in the skin, bones, lymph nodes or pituitary gland usually gets better with treatment and is called “low-risk.” Some patients have involvement in the spleen, liver, bone marrow, lung and skeleton. This is called “high-risk disease” and may be more difficult to treat. Some patients may develop long-term side effects such as diabetes insipidus, stunted growth, loss of teeth, bone defects, hearing loss, or neurologic problems; while other patients remain without side effects. In a minority of cases, the disease can be life-threatening.

Certain factors affect the chance of recovery and options for treatment. These factors include the extent of the disease, whether “risk organs” (liver, spleen, lung, bone marrow) are involved, and how quickly the disease responds to initial treatment.

Patients with LCH should usually have long term follow-up care to detect late complications of the disease or treatment. These may include problems of skeletal deformity or function, liver or lung problems, endocrine abnormalities, dental issues or neurological and neurocognitive dysfunction.

Please be advised that all the information you read here is not a replacement for the advice you will get from your consultant and their team.

Help ensure that we can continue to bring you this vital informational material, make a donation today

LCH in Children
The questions specifically relate to LCH in Children.

How is it diagnosed?

How is it diagnosed?

1. What causes LCH?
The cause of LCH is unknown. In recent years, it has become apparent that LCH cells carry one of a range of mutations (e.g. BRAF V600E, MAP2K) that causes these dendritic cells to act in an abnormal way, causing LCH. It is not yet clear why and how this mutation occurs, but this discovery provides us with potential targets for new experimental therapies. These mutations are not present in the cells of the rest of the body and are therefore not passed on in families

 

2. Is there a cure for LCH?
While some patients go into remission and may live normal lives with or without treatment, we usually don’t use the term “cure” with this disease. No specific amount of time without active disease has yet been established for adults to determine when a patient is considered to be cured.

3. What is considered to be remission?
Complete remission means that there is no evidence of disease, whereas partial remission means that most of the signs and symptoms of LCH are gone, but some still remain. Doctors use the term response and “non-active” to describe patients who are free of symptoms and signs of LCH. Usually a cure is linked to being in remission for a certain period of time. There is no established period of “non-active” disease before LCH is considered cured, but the chance for recurrence is low after five years from end of treatment.

4. Where did LCH get its name?
In 1868, the German pathologist Paul Langerhans discovered a type of white blood cell which eventually came to bear his name. The various manifestations of LCH were previously known by a number of different names (histiocytosis-X, eosinophilic granuloma, Letterer-Siwe disease, Hand-Schüller-Christian syndrome, etc.). In 1983, it was suggested that this disorder be named “Langerhans cell histiocytosis,” to recognize the key role of the Langerhans cell in all of the different manifestations.

5. Is LCH fatal?
It can be. A small percentage of patients, most often those with multisystem risk-organ involvement that is unresponsive to treatment, may not survive.

6. What are the different therapies/treatments commonly used to treat LCH?
Treatment is based upon the organ(s) involved, extent of disease and age of the patient. In some cases, no treatment is necessary. Others may respond to surgical removal, steroids, or anti-inflammatory drugs (NSAIDs). Low-dose radiation is helpful in some situations, but should be carefully used in children. There are patients who require chemotherapy such as vinblastine, vincristine, etoposide (VP-16), methotrexate, cytosine-arabinoside (Ara-C), and/or 6-MP. In patients with severe disease that does not respond to initial treatment, stronger chemotherapy combinations may be used. Ultraviolet light (PUVA) may be helpful for limited skin disease. In very rare instances, a transplant of the liver, lung, or bone marrow may be necessary.

7. Can an infant be tested at birth for LCH?
A biopsy of the affected tissue, rather than a blood test, is required for diagnosis and would therefore not be appropriate as a routine test unless this disease is suspected.

8. Is LCH hereditary?
Although there are rare families (less than 2% of all cases) documented with more than one member diagnosed with LCH, at this point, there is no clear evidence that this disease is inherited.

9. Signs,Symptoms & can LCH spread?
The symptoms of LCH will depend on which part of the body is affected and whether the disease is affecting more than one part of the body. The lymph glands may be enlarged, and the child may be irritable and have a poor appetite.
Pain in the bone and/or swelling and lumps on the skull can occur if LCH is affecting the bone. A skin rash such as cradle cap or nappy rash may occur if the skin is affected. A discharge from the ear or hearing problems can occur if the ear is affected. The child may have breathing difficulties if LCH affects the lungs or chest. Tummy problems such as diarrhoea and liver problems including jaundice can occur if LCH affects the gut or liver.
In 10–20% of patients with multi-system disease, the pituitary gland at the base of the brain is affected, causing hormonal problems. This can lead to the child passing larger amounts of urine and being very thirsty. This is called diabetes insipidus, which is different from sugar diabetes and can be well-controlled with specific medicines. Occasionally, other pituitary hormones may be affected, causing poor growth or delayed puberty, which can also be treated.

The exact mechanism that causes lesions to appear in other locations in the body is not yet known. However, some researchers believe that abnormal LCH cells travel through the blood like tumor cells and “seed” in different locations, creating new lesions.

10. How is LCH diagnosed?
A variety of tests and investigations may be needed to diagnose LCH. Tests are likely to include the removal of a sample of cells from an affected part of the body (a biopsy). This is usually done in an operation under a general anaesthetic. The cells are then examined under a microscope. X-rays are taken of the bones, the skull and the lungs. Blood and urine tests will also be done. Additional scans and tests may be required depending on which parts of your child’s body is affected. These tests help the doctors decide whether the disease is a single-system or multi system type.
When your child is having the tests, they may need to stay in hospital. Any tests and investigations that your child needs will be explained to you.

11. Is it true that LCH is mostly a childhood disease?
Not necessarily. Although we do know the incidence of childhood LCH, there is not enough data to determine how many adults are affected by this disease but because it is considered a childhood disease it is under diagnosed in adults.

12. With the diagnosis and treatment of LCH, is my child more likely to develop cancer?
Although this occurs rarely, LCH is associated with cancer more often than would be expected by chance. This can occur before, during, or after the diagnosis of LCH. Some cancers following the LCH diagnosis might be related to the treatments given. When cancer occurs before LCH, the histiocytosis might represent a “reaction” to the cancer itself.

13. What are permanent consequences of LCH?
Permanent consequences are also known as late effects of LCH, although they can occur early on. They are believed to be mostly related to the disease rather than treatment and include:
a. Diabetes Insipidus
b. Stunted growth
c. Bone abnormalities
d. Hearing loss
e. Neurological problems, including poor coordination, unsteadiness, difficulty with handwriting, abnormal eye movements, problems with speech, learning disabilities/decreased school performance, memory loss, and behavior difficulties.
f. Loss of teeth.
g. Loss of spinal height
h. Delayed puberty
i. Bulging eyes.
j. Scarring of lungs
k. Scarring of liver/cirrhosis
l. Secondary cancers

14. What are the chances my child will develop permanent consequences?
One or more permanent consequences are reported in an estimated 50% of all LCH patients, making long-term follow-up a necessity. Severity and type depends on the affected organs, number of lesions, and the treatment administered. Read more about permanent consequences of LCH.

15. What is Neuro degeneration?
Neuro degeneration is progressive loss of brain function. It occurs as a permanent consequence in some cases of LCH.

16. Can neuro degeneration be prevented/reversed/treated?
It is not currently known whether neuro degeneration can be prevented. It is believed that neuro degeneration cannot be reversed, and there is controversy whether patients with neuro degeneration can be successfully treated. There have been some promising results with Ara-C but more extensive scientific studies are required.

17. What is “PLCH?”
PLCH (pulmonary Langerhans Cell Histiocytosis) is LCH of the lung. It affects mostly adults who smoke and often occurs without other LCH involvement.

18. What kind of doctor should we use?
A pediatric oncologist most often provides primary treatment and coordinates a team of health professionals, which may include, but are not limited to, the primary care physician, pediatric surgeon, radiologist, pediatric nurses, and social workers.

19. What should I look for in a doctor?
LCH is most often followed and treated by an oncologist, who specializes in cancer-type illnesses. The level of experience with LCH can vary widely among physicians. If he/she is not knowledgeable about this disease, a willingness to learn more and consult with the experts can go a long way. Other qualities to look for are accessibility and good communication skills with you, as well as other physicians.

20. Will my child grow normally?
Most children with LCH do grow normally; it is believed that growth hormone deficiency affects approximately 10% of children with this disease.

21. What is the treatment for stunted growth related to LCH?
If stunted growth is due to growth hormone deficiency, which occurs in approximately 10% of LCH patients, it can be treated with daily injections of growth hormone under the supervision of an endocrinologist. The treatment is usually prescribed as long as the child is growing.

22. Is growth hormone treatment safe?
Growth hormone replacement appears to be safe and effective in LCH patients and is not associated with an increased risk of disease reactivation.

23. Are immunizations safe?
This is a controversial topic. Most researchers believe that children should wait 3-6 months after chemotherapy and/or steroids to take regular vaccinations, especially live-virus vaccinations such as influenza, MMR, and polio. There is no proof that vaccinations trigger LCH. It is important to consult with your physician regarding your child’s particular case.

24. What type of LCH involvement puts my child at higher risk for developing Diabetes Insipidus?
CNS risk lesions have been identified as lesions affecting the facial bones or the front or side(s) of the skull. These include the temporal (around the temples), sphenoidal (behind the sinuses), ethmoidal (between the eyes), zygomatic (cheekbone), and orbital (eye socket) bone with tumor extension into the brain. Involvement of these bones increases the risk of developing Diabetes Insipidus, which is the hallmark of CNS disease.

25. What are the chances my child will develop diabetes insipidus?
DI occurs in as many as 25% of all patients and as many as 50% of patients with multisystem LCH.

26. What are risk organs?
Risk organs include bone marrow, spleen, and liver and are more difficult to treat than other sites of involvement with LCH.

27. Follow-up care and What happens if my child has a recurrence or does not respond to treatment?
It is important to know that the vast majority of children will recover completely from LCH.
Some children however, are left with persistent/recurring problems and for a very small number of patients with multi-system LCH, it can be a life-threatening condition. After successfully completing treatment, patients will have follow-up clinic appointments. LCH sometimes comes back (‘reactivates’) and may need treatment again. If this happens, treatments for LCH that have worked for them before may be effective again. The same or different treatment may then be required. Patients are also monitored for possible permanent consequences of the disease (e.g. a low production of certain hormones, hearing problems) and may need treatment for these conditions.

If you have specific concerns about your child’s condition and treatment, it’s best to discuss them with your child’s specialist medical team who know the situation in detail.

If disease recurs after treatment, repeat of the same chemotherapy is often used but will depend on which organs are involved and the length of time since previous treatment. If LCH recurs immediately after therapy or does not improve with therapy, alternative treatment such as 2CdA, Ara-C, vincristine, methotrexate, or bisphosphonates may be used. Rare cases of risk-organ disease that is progressive and not responsive to treatment may require a RIC stem-cell transplant.

28. What is reduced-intensity conditioning (RIC)?
Reduced-intensity conditioning is a less toxic pre-transplant therapy with the goal of suppressing the patient’s immune system enough so that it will accept donor stem cells while reducing the side effects of high dose chemotherapy The RIC may be used in some HLH patients, as well as some LCH patients with severe, resistant disease.
Please be advised that all the information you read here is not a replacement for the advice you will get from your consultant and their team.

Possible Side Effects of Treatment

Side effects of treatment

Side effects of treatment

What are the side effects of vinblastine?
Side effects include:
a. Low blood counts (with higher risk of infection).Mild nausea/vomiting/constipation
b. Easily sunburned
c. Skin irritation at site of injection
d. Thin or brittle hair
e. Fatigue
f. Bone pain
g. Hoarseness
h. Seizures
i. Shortness of breath
j. Nerve damage (especially in adults) with tingling, numbness and/or pain of the hands and feet

 

What are the side effects of prednisone?
Side effects include:
a. Increase in blood sugar
b. Increase in appetite
c. Heartburn
d. Bloating/fluid retention/weight gain
e. Difficulty sleeping
f. Mood/behavior/personality changes
g. Higher risk of infection
h. Slow wound healing
i. Muscle weakness
j. Loss of bone calcium
k. Increased hair growth

More unusual side effects may include:
a. Problems with vision/eye pain
b. Seizures
c. Confusion

What are the side effects of methotrexate?
Side effects include:
a. Mouth sores/swollen, tender gums
b. Nausea/vomiting/diarrhea/decreased appetite
c. Low blood counts
d. Dizziness/drowsiness
e. Headache

More unusual side effects may include:
a. Blurred vision or loss of vision
b. Seizures
c. Confusion
d. Weakness/difficulty moving one or both sides of the body
e. Loss of consciousness
f. Lung damage
g. Allergic reactions

Side effects of treatment

Side effects of treatment

What are the possible side effects of 6-MP (mercaptopurine)?
More common signs/symptoms include:
a. Low blood counts (red cells, white cells, and clotting cells)
b. Nausea/vomiting/decreased appetite
c. Headache
d. Weakness/fatigue/achiness
e. Rash/darkening of the skin

 

What are the possible side effects of 2-CdA (cladribine/leustatin)?
More common signs/symptoms include:
a. Flu-like symptoms (Fever, chills, headache, fatigue, nausea/vomiting)
b. Decreased appetite
c. Constipation
d. Low blood counts (red cells, white cells, and clotting cells)
e. Skin rash/redness/itching

The answers to the following questions may be found in the Support Information – A Parent’s Guide

THE DISEASE
How is it diagnosed?
How is it treated?
What are the clinical trials?

COPING
How do I cope with the diagnosis?
How do I get the information I want?
How do I talk to my child and their siblings about this?
How do we deal with the treatment?
What happens at the end of the treatment?
What resources are there for sibling or family support?
Where can I get financial support?
How do I find other parents?

Please be advised that all the information you read here is not a replacement for the advice you will get from your consultant and their team.

LCH Newsfeed

pubmed: langerhans cell hist...

NCBI: db=pubmed; Term=langerhans cell histiocytosis

Related Articles

A Case of Unicentric Castleman Disease and Langerhans Cell Histiocytosis: Two Entities in One Lymph Node.

Clin Lab. 2018 Oct 31;64(11):

Authors: Liu X, Liu L, Zhang L, Zhuo M, Xiao R, Lin D, Fang Z

Abstract
<i>Background:</i> Castleman disease (CD) is a lymphoproliferative disorder and Langerhans cell histiocytosis (LCH) is a clonal disease of the monocyte-macrophage system. The authors describe a rare case of CD coexistent with LCH at diagnosis in one lymph node. <i>Methods:</i> Hematologic investigation and intrapulmonary mass biopsy were performed. <i>Results:</i> The patient achieved complete remission and, up to now, no signs of recurrence were found. <i>Conclusions:</i> The report about co-existence with CD and LCH will promote correct diagnosis because of the recognition of this rare morphologic combination. An adequate amount of tissue should be obtained to avoid missing the diagnosis.

PMID: 30549992 [PubMed - in process]

Your voice

Share your voice - Your story LCH

Fifi's Story by Mum - Tiffany Rumble

Fifi's story - Paediatric Langerhans Cell Histiocytosis Diagnosis, treatment and raising essential funds for research.



Isobel's Story by Mum & Dad Suzanne & Mike Parmenter


Title:Running a chemo house for a child- Kristina Smith

Living in and running your house and home when you are looking after a child on chemo. Top tips on what to do, useful products and where to buy them, and how easy it is once you get over the initial shock of diagnosis and discharge from hospital.


Title:LCH Paediatric - Sebbie’s Story by Mum,Kristina Smith.

Intro:
In May 2015, my beautiful little boy was diagnosed with a very rare cancer like condition called LCH Langerhans’s Cell Histiocytosis. He was two and a half.

He had lost two kilos in two months. His left eye was partially closed from a skull tumour. His scalp was a bloody mess. His skin was covered in spots. His ears were oozing with infection. He had an insatiable thirst to the point of drinking rain water from the trampoline. He had lost his wonderful zest for life.

After almost two years of repeated GP visits, seeing dermatology and ENT at the hospital and advice from all quarters we finally got diagnosed on Northbrook Ward in Winchester hospital.

Only 50 kids a year get this wicked illness in the UK. Nobody knows why, or how. It's so rarely seen that its diagnosis is often missed by doctors for some time.

Within three days, our little Sebbie had been through hell. He'd had cannulas, scans, prodding and poking, general anaesthetic, a central line fitted in his chest, and was away from his home and new baby brother. We were transferred to the excellent Piam Brown paediatric oncology ward at Southampton Hospital. Sebbie was put on chemo immediately.

Sebbie's chemo was meant to last 12 months, but his LCH kept returning, so it was extended to 18 months, including 3 sets of 'intensive' sessions lasting 6 weeks, which were hell.

Sebbie's pituitary gland has been damaged for life so he has to take tablets three times a day every day to stop his body weeing to death. His skull tumours have all disappeared. His skin now looks amazing. He now has his old mop of blonde hair back. We visit Northbrook Ward in Winchester every 3 weeks for chemo with the wonderful Dr Ian Rodd. Every three sessions we return to Piam Brown for the excellent Dr Ramya to check on progress.

Sadly, in November 2016, we finally had our 'end of treatment' consultation booked at PB. Excited, but apprehensive, we never expected the news we received. They have now found a 'flare' on his cerebellum (brain) consistent with the even rarer Neurodegenerative LCH (ND-LCH).

Our luck has just got a whole lot worse. There is no known treatment for ND-LCH, and trials on drugs are limited due to the incredibly small number of sufferers across the world, and the unknown long term effects of the treatments that have been trialled. Sebbie is now undergoing 3 monthly neurology testing (the 'Ataxia test'), with psychological testing tbc, to pinpoint the first signs of neurodegeneration. This is likely to ultimately end with severe physical and learning disability.

When that inevitable day happens, we will need to make a decision, cloaked in uncertainty, on what treatment option we take. He has now been referred to Great Ormond Street Hospital in London to the national expert in ND-LCH, and is undergoing BRAF gene mutation testing. 50 per cent of LCH patients have mutations to their BRAF gene which can be treated with mutation inhibitors, although the long term effects are unknown, and they are not thought to have any effect on the ND-LCH, just any reactivation of his LCH. Our other option now is even stronger chemotherapy.

So that's our story. My child happens to be that one in a million. Luckily My Sebbie is SO incredibly brave. He still doesn't know he's ill. He gets frustrated that he cant go to soft play or playgroup, go for a swim or dig for mud in the garden, but his immunity is low and his central line has to be protected.

In April 2016, I shared an abseil with five other Mummies from Sebbie’s preschool, Rainbows Playgroup. They have been amazing. They are a parent led preschool that runs in the local church. They’ve recently been awarded outstanding by Ofsted. Rainbows keep Sebbie feeling 'normal', beavering in the background to give him separate sand play, water play and snacks; being trained by the community nurse on dealing with any emergency; and being really supportive throughout.

Hopefully Sebbie will recover. There are many more children around the World that are being diagnosed with LCH. All with similar stories I'm sure. So please give generously to fund more research, and particularly ND-LCH. LCH doesn't have the public's awareness, or support, like other childhood cancers but it can be just as devastating.


Share your story with the media

By raising awareness of histiocytosis in the national and local press we can reach more people. We rely on personal stories to help us engage readers around our cause and bring our stories to life.

If you are interested in sharing your story on our website or in a magazine, newspaper or on TV please send a 100-word summary of your story along with your name, contact details and a recent photo to Histio@histiouk.org. We regret that we are unable to respond to everyone, but we really appreciate you getting in touch.

Why should I share my story?
We want to help as many people as possible during their histiocytosis experience – patients, carers, families and communities. By raising awareness of what we do in national newspapers, magazines, on TV and in the local press we can reach more people.

We rely on personal stories to help us do this as they engage the reader and bring the story to life. For example, if we provide research for a newspaper showing that histiocytosis can affect people financially it has more of an impact if it’s accompanied by an emotive quote or story of someone who has been directly affected and helped by us.

Your story can encourage those who see it to get help if they are worried they have the symptoms of histiocytosis or may inspire them to donate or fundraise for us. Some people who have shared their story find it a cathartic experience. It makes them feel good to give something back.

Where would my story appear?
As well as our website, we work with a range of media from broadcasters like the BBC, national newspapers like The Times, Daily Mail and Guardian and women’s magazines like Woman’s Own and Good Housekeeping.

They all have different requirements for their stories so we would approach those which we think are most appropriate, depending on your story.

Do I have to be identified/pictured?
Yes, all of the magazines and newspaper ask that the people they interview are pictured. Some ask you to send/email them photos to use while others send a photographer to take photos.

Will I have a say over what’s written?
By sending us your story you agree to its publication on our website or on or in any publication that may collect news feeds or create editorial content.

Request by journalist for contact details will be agreed with you in advance of disclosure.

Please be aware that whilst some journalists offer to read your story before it goes to print to check facts it depends on the publication and this cannot be guaranteed.

What happens next?
The journalist will try tell you when your story will appear so you can get a copy and tell all your friends. We ask the journalists to include information about Histiocytosis UK Support’s campaigns and services and you can feel proud that you’ve helped deliver our message.

If you are interested in sharing your story in a magazine, newspaper or on TV please send a 100-word summary of your story along with your name, contact details and a recent photo to Histio@histiouk.org. We regret that we are unable to respond to everyone, but we really appreciate you getting in touch.

The views expressed are those of the writer and participants and do not reflect views and or opinions of the charity any products mentioned are available from a variety of retailers.

Help ensure that we can continue to bring you this vital informational material, make a donation today

Please use the form below to contact Histio UK

When we are out of the office and over holiday periods we have limited access to email and telephone. We will respond to your enquiry as soon as it is possible or upon our return. Thank You.

Telephone: 01733 309619 - Please note this is not a 24 hour number - 9am to 5.30pm

Your Name (required)

Your Email (required)

Subject

Your Message

Please answer the question